| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net Income (Loss) Attributable to Parent | ||||||
-85,472 | -56,900 | -28,047 | -13,332 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation expense | ||||||
8,165 | 6,059 | 1,542 | 419 | |||
Depreciation expense | ||||||
1,764 | 1,900 | 800 | 500 | |||
Change in fair value of warrant and debt derivative liability | ||||||
0 | 406 | 301 | 20 | |||
Net (accretion of discount)/amortization of premium on marketable securities | ||||||
164 | 0 | 0 | - | |||
Non-cash interest expense | ||||||
255 | 103 | 35 | 28 | |||
Gain on sale of fixed assets, net | ||||||
2 | 0 | 0 | - | |||
Changes in assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
-372 | 3,052 | 347 | 3 | |||
Accounts payable | ||||||
-585 | -221 | 774 | -43 | |||
Accrued expenses and other current liabilities | ||||||
3,694 | 3,594 | 1,733 | 273 | |||
Other liabilities | ||||||
-7 | 843 | -90 | - | |||
Other liabilities | ||||||
- | - | - | -171 | |||
Net cash used in operating activities | ||||||
-71,980 | -47,279 | -23,265 | -12,314 | |||
Investing activities | ||||||
Purchase of investments | ||||||
0 | 136,087 | 0 | 0 | |||
Proceeds from sales and maturities of investments | ||||||
55,000 | 81,250 | 0 | 0 | |||
Cash acquired in the 2016 acquisition of Epiva | ||||||
- | - | - | 10,486 | |||
Purchases of property and equipment | ||||||
3,032 | 5,462 | 1,742 | 1,250 | |||
Proceeds from sale of fixed assets | ||||||
2 | 171 | 0 | 27 | |||
Net cash (used in)/provided by investing activities | ||||||
51,970 | -60,128 | -1,742 | 9,263 | |||
Financing activities | ||||||
Net proceeds from the issuance of common stock upon completion of initial public offering | ||||||
0 | 75,829 | 0 | 0 | |||
Deferred issuance costs | ||||||
0 | 0 | 15 | 0 | |||
Net proceeds from the issuance of convertible preferred stock | ||||||
0 | 81,336 | 48,903 | 7,495 | |||
Proceeds from Issuance of Long-term Debt | ||||||
19,481 | 4,975 | 0 | 11,000 | |||
Settlement of derivative liability | ||||||
0 | 250 | 0 | 0 | |||
Proceeds from the exercise of stock options | ||||||
511 | 122 | 79 | 247 | |||
Repayment of long-term debt | ||||||
15,000 | 0 | 0 | 4,000 | |||
Change in stockholders' payable | ||||||
- | - | - | 1,000 | |||
Net cash provided by financing activities | ||||||
4,992 | 162,012 | 48,967 | 15,742 | |||
Net (decrease) increase in cash, cash equivalents and restricted cash | ||||||
-15,018 | 54,605 | 23,960 | 12,691 | |||
Supplemental disclosure of cash flow information | ||||||
Cash paid for interest | ||||||
1,166 | 742 | 437 | 204 | |||
Noncash investing and financing activities | ||||||
Conversion of convertible preferred stock into common stock upon closing of initial public offering | ||||||
0 | 165,778 | 0 | 0 | |||
Conversion of convertible preferred stock warrants into common stock warrants | ||||||
0 | 819 | 0 | 0 | |||
Property and equipment additions in accounts payable and accrued expenses | ||||||
246 | 348 | 84 | 0 | |||
Issuance of debt derivative liability in connection with long-term debt facility | ||||||
0 | 150 | 0 | 0 | |||
Issuance of warrants in connection with long-term debt facility | ||||||
0 | 89 | 0 | 76 | |||
Accretion of convertible preferred stock to redemption value | ||||||
0 | 0 | 32 | 1,645 | |||
Long-term debt assumed in acquisition of Epiva, net of discount | ||||||
- | - | - | 2,923 | |||
Net non-cash assets acquired in acquisition of Epiva | ||||||
- | - | - | 57 | |||